Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference

Core Insights - Telo Genomics Corp. will present at the OTCQB Venture Virtual Investor Conference on August 7, 2025, focusing on its new strategy for developing and commercializing multiple myeloma assays [1][2]. Company Overview - Telo Genomics is a biotech company specializing in diagnostic and prognostic tests through telomere analysis, with applications in oncology and neurological diseases [5]. - The company is developing a comprehensive telomere platform, including liquid biopsies, which are less invasive and more easily replicated than traditional diagnostic methods [5]. - Telo Genomics has substantiated its technology through over 160 peer-reviewed publications and 30+ clinical studies involving more than 3,000 patients with various cancers and Alzheimer's disease [5]. Event Details - The presentation will be live and interactive, allowing investors to ask questions in real-time, and will be led by Guido Baechler, Executive Chairman of the Board [2][3]. - The event is scheduled for August 7, 2025, from 1:00 PM to 1:30 PM ET, with an archived webcast available afterward [3]. Industry Context - The liquid biopsy field is rapidly growing and is of significant interest to the medical community due to its less invasive nature compared to traditional diagnostics [5].